Novo Nordisk's (NOVOB.DK) shares dip about 16% due to the company lowering its full-year 2025 sales and operating profit outlook. Previously, investors had higher expectations for Novo Nordisk’s growth rates, but the updated guidance now forecasts sales growth in the 8–14% range for the year, which is below earlier projections (13-21%).
Today’s moves are largely due to weaker-than-expected Wegovy sales in the U.S. obesity market. The updated sales outlook specifically cites reduced growth expectations for Wegovy in the U.S., as well as slower-than-expected market expansion and stronger competition, particularly from Eli Lilly's rival drug Zepbound.
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile app
NOVOB shares are back at multi-year lows after cutting forecast. Source: xStation
This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.
